ranibizumab, an ophthalmic drug that binds to the receptor binding site of active forms of vascular endothelial growth factor A. ▪ INDICATIONS: This drug is used in the treatment of neovascular macular degeneration. ▪ CONTRAINDICATIONS: Ocular infections and known hypersensitivity to this drug prohibit its use. ▪ ADVERSE EFFECTS: Adverse effects of this drug include dizziness; headache; blepharitis; cataract; conjunctival hemorrhage and hyperemia; detachment of the retinal pigment epithelium; dryness, irritation, and pain in the eye; visual impairment; vitreous floaters; ocular infection; constipation; nausea; hypertension; urinary tract infection; thromboembolism; bronchitis; cough; sinusitis; and upper respiratory infection.
